Evidence for a "window of opportunity" in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicenter cohort study.
CONCLUSION: Inverse correlation between therapeutic delay and clinical response was found, supporting early adalimumab use and providing evidence for a "window of opportunity" in HS. Adalimumab efficacy and safety were confirmed, along with patients' QoL improvement. Immunosuppressants could negatively influence response to adalimumab inducing a switch to non-TNFα -driven pathways.
PMID: 32119111 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Marzano AV, Genovese G, Casazza G, Moltrasio C, Dapavo P, Micali G, Sirna R, Gisondi P, Patrizi A, Dini V, Bianchini D, Bianchi L, Fania L, Prignano F, Offidani A, Atzori L, Bettoli V, Cannavò SP, Venturini M, Bongiorno MR, Costanzo A, Fabbrocini G, Peri Tags: Br J Dermatol Source Type: research
More News: Dermatology | Hidradenitis | Humira | Italy Health | Pain | Skin | Smokers | Study | UK Health